Public disclosures

Cobo Marc

Company insiders · Principal Accounting Officer · BridgeBio Oncology Therapeutics, Inc.

Advertisement
FollowLatest SEC filingSEC filer historyProfile details as reported on 2026-11-17.Following & alerts
Reported transaction lines
1
Buy lines
0
Sell lines
1

Filing activity by month

Original filing lines in up to 12 months with activity.

  • 2026-111

Frequently disclosed stocks

Disclosure history

More filters
Clear filters
Reporting investorSecurityActivityTransaction / periodFiledReported amountSource
Cobo Marc

Principal Accounting Officer · BridgeBio Oncology Therapeutics, Inc.

BBOT

BridgeBio Oncology Therapeutics, Inc.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 13734 · SEC code covers open-market or private transactions · This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on July 24, 2026.

2026-11-132026-11-17

≈ $184.86

78 shares/units

SEC 4

Counts describe original filing lines in BriefStock’s coverage. Later amendments can correct or supplement them. Check the original filing for ownership and transaction details.

Advertisement